Alda Pharmaceuticals Corp (C:APH)
Shares Issued 43,417,799
Last Close 1/24/2008 $0.41
Friday January 25 2008 - News Release

Dr. Terrance Owen reports

ALDA'S T36(R) SUCCESSFULLY COMPLETES FIRST CLINICAL TESTS

Alda Pharmaceuticals Corp. has received results from clinical tests of its T36 formulation for use as a skin antiseptic, a hygienic hand rub, a presurgical hand wash and a preinjection scrub. In these clinical studies, T36 demonstrated complete efficacy after only 30 seconds of exposure to all six species of bacteria tested, including VRE (vancomycin-resistant enterococcus), MRSA (methicillin-resistant staphylococcus aureus) and MDR (multidrug resistant) enterococcus faecium. These three species of bacteria are critical concerns in hospitals, nursing homes and other medical facilities based on their resistance to many antibiotics and other treatments. The clinical testing was completed according to the standards required by the FDA in the United States, Health Canada and the European Medicines Agency, which included exposure of the bacteria to T36 for periods ranging from 30 seconds to 30 minutes.

Dr. Terrance Owen, president and chief executive officer, states: "We were confident that T36 would do well in these tests given the extensive studies that ALDA has already done using three-minute exposure times and the successful one-minute test against MRSA that we announced on Dec. 6, 2007. However, we needed to conduct new tests to meet the specific requirements of the regulatory agencies in Canada, Europe and the U.S. We are very pleased that T36 performed extremely well in these tests. With this data, we can now start planning human trials for Canada and the EU, as well as preparing for our pre-IND (investigational new drug) meeting with the FDA. After that meeting, we will know precisely what further testing is required before starting human trials for submission to the FDA."